AIM
HUMA icon

Aigen Investment Management’s Humacyte HUMA Stock Holding History

Aigen Investment Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,611
Closed -$24.3K – 922
2025
Q2 		$24.3K Buy
+11,611
New +$22.3K ﹤0.01% 750

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Aigen Investment Management's HUMA Position: Q3 2025 in Review

Aigen Investment Management sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 11,611 shares — an estimated $24.3K sold.

Aigen Investment Management first reported a position in HUMA in Q2 2025 and held it in 1 quarter. The position peaked at $24.3K in Q2 2025. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Aigen Investment Management reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Aigen Investment Management sold 11,611 Humacyte shares in Q3 2025, an estimated $24.3K.
  • Aigen Investment Management first reported a position in Humacyte in Q2 2025 and held it in 1 quarter.
  • Aigen Investment Management's Humacyte position peaked at $24.3K in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Aigen Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.